Azacitidine + Ascorbic Acid for myeloproliferative disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Jan 2018: Trial registered, NCT03397173
  2. 16 Mar 2018: Trial started, NCT03397173

The trials

NCT03397173: TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

State
Completed
Phase
Phase 2
People
12 taking part
Started
16 Mar 2018
Primary completion
3 Jan 2021
Arms
Azacitidine + Ascorbic acid
Results
None posted
  1. 11 Jan 2018: Trial registered
  2. 16 Mar 2018: Trial started
  3. 21 Jan 2021: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.